Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results

References

• Hake C-M. Kontroll av blodsocker blir allt sämre – varför? Diabetolognytt 2011;24: e-pub
   Google Scholar
• Chiu CJ, Wray LA. Factors predicting glycemic control in middle-aged and older adults with type 2 diabetes. Prev Chronic Dis 2010;7:A08
   PubMed Web of Science ®Google Scholar
• Fakhoury WK, Lereun C, Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010;86:44–57
   PubMed Web of Science ®Google Scholar
• Philippe J, Raccah D. Treating type 2 diabetes: how safe are current therapeutic agents? Int J Clin Pract 2009;63:321–32
   PubMed Web of Science ®Google Scholar
• Bøgelund M, Vilsbøll T, Henriksen JE, et al. Patient preferences for diabetes management among people with type 2 diabetes in Denmark – a discrete choice experiment. Curr Med Res Opin 2011;27:2175–83
   PubMed Web of Science ®Google Scholar
• Dranitsaris G, Longo CJ, Grossman LD. The economic value of a new insulin preparation, Humalog Mix 25. Measured by a willingness-to-pay approach. Pharmacoeconomics 2000;18:275–87
   PubMed Web of Science ®Google Scholar
• Jendle J, Torffvit O, Ridderstrale M, et al. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes. Curr Med Res Opin 2010;26:917–23
   PubMed Web of Science ®Google Scholar
• Lloyd A, Nafees B, Barnett AH, et al. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes. Clin Ther 2011;33:1258–67
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39–47
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473–81
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brändle M, et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268–78
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009;32:84–90
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met + SU): a randomised controlled trial. Diabetologia 2009;52:2046–55
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met + TZD). Diabetes Care 2009;32:1224–30
   PubMed Web of Science ®Google Scholar
• Bogelund M, Vilsboll T, Faber J, et al. Patient preferences for diabetes management among people with type 2 diabetes in Denmark - a discrete choice experiment. Curr Med Res Opin 2011;27:2175–83
   PubMed Web of Science ®Google Scholar
• Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab 2009;11:1163–72
   PubMed Web of Science ®Google Scholar
• Liu JT, Tsou MW, Hammitt JK. Willingness to pay for weight-control treatment. Health Policy 2009;91:211–8
   PubMed Web of Science ®Google Scholar
• Egede LE, Nietert PJ, Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 2005;28:1339–45
   PubMed Web of Science ®Google Scholar
• Jansen HJ, Vervoort G, van der Graaf M, et al. Pronounced weight gain in insulin-treated patients with type 2 diabetes mellitus is associated with an unfavourable cardiometabolic risk profile. Neth J Med 2010;68:359–66
   PubMedGoogle Scholar
• Sjoberg N, Brinkworth GD, Wycherley TP, et al. Moderate weight loss improves heart rate variability in overweight and obese adults with type 2 diabetes. J Appl Physiol 2011;110:1060–4
   PubMedGoogle Scholar
• Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care 2011;34:1481–6
   PubMed Web of Science ®Google Scholar
• Feldstein AC, Nichols GA, Smith DH, et al. Weight change and glycemic control after diagnosis of type 2 diabetes. J Gen Intern Med 2008;23:1339–45
   PubMed Web of Science ®Google Scholar
• Feldstein AC, Nichols GA, Smith DH, et al. Weight change in diabetes and glycemic and blood pressure control. Diabetes Care 2008;31:1960–5
   PubMed Web of Science ®Google Scholar
• Anderson JW, Kendall CW, Jenkins DJ. Importance of weight management in type 2 diabetes: review with meta-analysis of clinical studies. J Am Coll Nutr 2003;22:331–9
   PubMed Web of Science ®Google Scholar
• Gregg EW, Gerzoff RB, Thompson TJ, et al. Trying to lose weight, losing weight, and 9-year mortality in overweight U.S. adults with diabetes. Diabetes Care 2004;27:657–62
   PubMed Web of Science ®Google Scholar
• Wolf AM, Siadaty M, Yaeger B, et al. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). J Am Diet Assoc 2007;107:1365–73
   PubMed Web of Science ®Google Scholar
• Yu AP, Wu EQ, Birnbaum HG, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. Curr Med Res Opin 2007;23:2157–69
   PubMed Web of Science ®Google Scholar
• Louviere JJ, Timmermans HJP. Stated preference and choice models applied to recreation research: a review. Leisure Sci 1990;12:9–32
   Google Scholar
• Ryan M, Watson V. Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Health Econ 2009;18:389–401
   PubMed Web of Science ®Google Scholar